Global Myelodysplastic Syndrome Drugs Market Projected to Grow at 9.7% CAGR, Reaching $3.58 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Myelodysplastic Syndrome Drugs Industry Market Size Be by 2025?
In recent times, the market for drugs treating myelodysplastic syndrome has expanded significantly. The market size, which was around $2.25 billion in 2024, is expected to escalate to nearly $2.47 billion in 2025, reflecting a 9.8% compound annual growth rate (CAGR). The surge over the prior period can be credited to an increase in the elder population, advancements in diagnostic methods, instances of MDS related to chemotherapy, a rise in cancer survivor rates, and developments in clinical research and drug discovery.

What's the Long-Term Growth Forecast for the Myelodysplastic Syndrome Drugs Market Size Through 2029?
The market size of drugs for myelodysplastic syndrome is expected to experience a robust increase in the upcoming years. The market is anticipated to escalate to "$3.58 billion in 2029, with a compound annual growth rate (CAGR) of 9.7%. Factors contributing to this growth during the forecast period include the increase in older population, advancements in targeted therapies, better comprehension of disease mechanisms, rising awareness and early diagnosis, and the expansion of oncology research. Notable trends during this forecast period consist of optimized erythropoiesis-stimulating agents, combination treatments, increased emphasis on iron chelation therapy, regulatory approvals and market accessibility, and patient-oriented care models.

View the full report here:
https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-drugs-global-market-report

What Are the Key Growth Drivers Fueling the Myelodysplastic Syndrome Drugs Market Expansion?
The surge in occurrences of myelodysplastic syndrome is anticipated to stimulate the expansion of the myelodysplastic syndrome drug market in the forthcoming years. Characterized by abnormal growth and maturation of bone marrow blood cells, Myelodysplastic syndrome (MDS) represents a group of disorders. This type of blood cancer significantly affects the generation of healthy blood cells. Drugs for myelodysplastic syndrome are utilized in its treatment, involving the modulation or inhibition of the immune system to reduce the need for red blood cell transfusions. As the American Journal of Managed Care reported in October 2022, the cases of myelodysplastic syndrome in the USA range between 60,000 and 175,000. As a consequence, the rise in myelodysplastic syndrome incidences is bolstering the growth of its related drug market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10675&type=smp

What Are the Key Trends Driving Myelodysplastic Syndrome Drugs Market Growth?
The myelodysplastic syndrome drugs market is focusing on telomerase inhibitors. In June 2024, US-based Geron Corporation introduced Rytelo (imetelstat), an FDA-approved IV telomerase inhibitor for LR-MDS patients with transfusion-dependent anemia. The treatment improves hemoglobin and offers transfusion independence with a manageable safety profile.

How Is the Myelodysplastic Syndrome Drugs Market Segmented?
The myelodysplastic syndrome drugs market covered in this report is segmented -

1) By Therapeutic Class: Immunomodulatory Drugs, Hypomethylating Agents, Anti-anemics
2) By Type of Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts
3) By Route of Administration: Oral, Parenteral
4) By Applications: Original, Generics
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers

Subsegments:
1) By Immunomodulatory Drugs: Thalidomide, Lenalidomide, Pomalidomide
2) By Hypomethylating Agents: Azacitidine, Decitabine, Guadecitabine
3) By Anti-anemics: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion Products

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10675&type=smp

Which Companies Are Leading the Charge in Myelodysplastic Syndrome Drugs Market Innovation?
Major companies operating in the myelodysplastic syndrome drugs market include Amgen Inc., Celgene Corporation, Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Lupin Ltd., Onconova Therapeutics Inc., Sun Pharmaceutical Industries Limited, FibroGen Inc., Aprea Therapeutics, Bayer AG, Bristol Myers Squibb, Celator Pharmaceuticals, Crystal Genomics Inc., AbbVie Inc., Astex Pharmaceuticals Inc., Geron Co., Hikma Pharmaceuticals plc, Jazz Pharmaceuticals Inc., Mylan NV, Novartis AG, Sandoz Inc., Syros Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Acceleron Pharma Inc., Agios Pharmaceuticals Inc., Incyte Corporation, Array Biopharma Inc., MEI Pharma Inc.

Which Regions Are Leading the Global Myelodysplastic Syndrome Drugs Market in Revenue?
North America was the largest region in the Myelodysplastic syndrome drugs market in 2024.Asia-Pacific is expected to be the fastest growing region in the global myelodysplastic syndrome drugs market report during the forecast period. The regions covered in the myelodysplastic syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10675

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.